Food and Drug Administration (FDA) director general Eric Domingo on Tuesday said Sinovac has submitted Phase 3 clinical trials results of its COVID-19 vaccine for emergency use authorization (EUA).
Domingo said Sinovac applied for EUA on January 13 but only submitted the results of its Phase 1 and 2 clinical trials.
“Sinovac applied in January but they only gave us the clinical trial results last week. So our experts are now taking a look at it,” he said in an interview on ANC.
“I know that I am having a meeting with them tomorrow so that we can see if we need more clarification,” he added.
According to Domingo, experts from the FDA will conduct a thorough evaluation of the results since they have not been published yet in any peer-reviewed journal.
With the initial batch expected to arrive this February, the Philippines has secured 25 million doses of the COVID-19 vaccine from Chinese firm Sinovac.
Vaccine czar Secretary Carlito Galvez Jr. earlier said the government is negotiating for the delivery of the initial 500,000 COVID-19 doses of vaccine from Sinovac.
The Philippine government aims to secure around 148 million doses of COVID-19 vaccines to inoculate some 50 to 70 million Filipinos this year.?— Joviland Rita/RSJ, GMA News
This article FDA’s Domingo: Sinovac has submitted Phase 3 trial results for EUA was originally published in GMA News Online.